Title:
MUTANT PROTEIN FOR PROLIFERATING REGULATORY T CELL
Document Type and Number:
WIPO Patent Application WO/2021/228253
Kind Code:
A1
Abstract:
Disclosed are an IL-2 mutant, a fusion protein or conjugate comprising the IL-2 mutant, and a pharmaceutical composition comprising the IL-2 mutant, fusion protein or conjugate. Compared with wild-type IL-2, the IL-2 mutant has reduced binding to IL-2Rβγ dimer, retains the biological activity thereof, and preferentially stimulates the proliferation of regulatory T cells. The IL-2 mutant can be used for treating autoimmune diseases, and does not have various side effects caused by immunotherapy by means of using natural IL-2.
Inventors:
HU HUI (CN)
Application Number:
PCT/CN2021/093944
Publication Date:
November 18, 2021
Filing Date:
May 14, 2021
Export Citation:
Assignee:
SHANGHAI GP BIOTECH CO LTD (CN)
International Classes:
A61K38/20; C07K14/55; A61P17/00; A61P19/02; A61P29/00; A61P31/14; A61P31/18; A61P35/00; A61P37/02; C07K1/107; C07K19/00; C12N5/10; C12N15/26; C12N15/62; C12N15/85
Domestic Patent References:
| WO1990010070A1 | 1990-09-07 | |||
| WO2003015697A2 | 2003-02-27 | |||
| WO2020057645A1 | 2020-03-26 |
Foreign References:
| CN111944036A | 2020-11-17 | |||
| CN111944008A | 2020-11-17 |
Attorney, Agent or Firm:
XU&PARTNERS, LLC. (CN)
Download PDF:
Previous Patent: CACHE DETERMINING METHOD AND APPARATUS
Next Patent: LITHIUM NIOBATE WAVEGUIDE HAVING WEAK PHASE DRIFT
Next Patent: LITHIUM NIOBATE WAVEGUIDE HAVING WEAK PHASE DRIFT